Periodic safety update reports (PSURs)

This page includes information on periodic safety update reports (PSURs), PSUR submission requirements, PSUR single assessment procedures (PSUSAs) and the European Union reference dates (EURD) list.

PSURs are pharmacovigilance documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation.

The objective of the PSUR is to present a comprehensive and critical analysis of the risk-benefit balance of the product, taking into account new or emerging safety information in the context of cumulative information on risk and benefits

EMA and national competent authorities assess information in PSURs to determine if there are new risks identified for a medicine and/or if its risk-benefit balance has changed.

A PSUR assessment can determine if further investigations on a specific issue are needed, or if an action is necessary to protect public health (e.g. an update of the information provided to healthcare professionals and patients).

Marketing authorisation holders (MAHs) are legally required to submit PSURs, in line with Regulation (EU) No 1235/2010, Directive 2010/84/EU and Commission Implementing Regulation (EU) No 520/2012.

Article 35 of the Commission Implementing Regulation describes the structure of PSURs. PDF icon Module VII of the Guidelines on Good Pharmacovigilance Practices (GVP) provides guidance on the preparation, submission and assessment of PSURs.

This format is a legal requirement for both nationally authorised products and centrally authorised products.

Preparation of PSURs

MAHs should consult the following information when preparing a PSUR:

The Agency has also published an explanatory note to GVP module VII, which all MAHs should consult when preparing PSURs. It addresses specific challenges in the EU single assessment procedure for nationally authorised products, but the issues may also apply to centrally authorised products.

For more information on GVP modules, see Good pharmacovigilance practices.

Specific guidance is available on preparing PSURs for COVID-19 vaccines:

Submission of PSURs

As of 13 June 2016, MAHs are required to submit all PSURs in the EU to the central PSUR repository using the eSubmission Gateway/ Web Client.

Use of the PSUR repository is mandatory for both centrally and nationally authorised medicines, whether they follow the EU single assessment or a purely national assessment procedure.

For more information on how to use the PSUR repository, see:

Further information on the PSUR repository, guidance on how to register and multimedia tutorials for MAHs on how to submit a PSUR in the correctly-structured electronic formats can be found on EMA's eSubmission website.

Submission requirements and EU reference dates: the EURD list

MAHs for active substances and combinations of active substances that are subject to assessment at EU level must submit the relevant PSURs according to the requirements set up in the list of EU reference dates (EURD) list:

The list does not include substances assessed at national level, although their PSURs must nonetheless be submitted via the PSUR repository. For these active substances, the frequency of submission is established at national level. For more information, see:

The EURD list provides the following information for each active substance/combination it contains:

  • frequency of PSUR submission;
  • data lock point;
  • submission date;
  • requirements for the submission of PSURs for generic, well-established use, homeopathic and traditional herbal products.

The EURD list is a legally binding document and MAHs are legally responsible for complying with its requirements. The list overrules the 'standard' PSUR submission cycle and any conditions related to the frequency of PSUR submission included in a marketing authorisation.

EMA updates the EURD list every month, following adoption by the Committee for Medicinal Products for Human Use (CHMP) and Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh), after consultation with the Pharmacovigilance Risk Assessment Committee (PRAC).

Any amendment to the EURD list becomes effective six months after its publication.

For more information on the EURD list and answers to frequently-asked-questions, see the following document:

MAHs and other stakeholders can request amendments to the EURD list by emailing with the following information:

Before submitting a request, EMA encourages stakeholders to carefully consult the introductory cover note. There may be some delay before EMA is able to respond due to the high volume of requests and necessary processing time.

Assessment of PSURs

PSURs submitted in accordance with the EURD list are subject to the EU PSUR single assessment (PSUSA) procedure.

EMA carries out PSUSA procedures to assess PSURs of medicines containing the same active substances or combinations, even if they are subject to different marketing authorisations and are authorised in different EU Member States. This aims to harmonise and strengthen benefit-risk review of medicines across the European Economic Area.

For more information, see the questions-and-answers below and Periodic safety update report single assessments.

Post-authorisation procedural advice: questions and answers


How useful was this page?

Add your rating
68 ratings
37 ratings
26 ratings
30 ratings
14 ratings